000134807 001__ 134807
000134807 005__ 20240229105041.0
000134807 0247_ $$2doi$$a10.1186/s13014-018-1026-x
000134807 0247_ $$2pmid$$apmid:29739417
000134807 0247_ $$2pmc$$apmc:PMC5941671
000134807 0247_ $$2altmetric$$aaltmetric:70394608
000134807 037__ $$aDKFZ-2018-00598
000134807 041__ $$aeng
000134807 082__ $$a610
000134807 1001_ $$aEl Shafie, Rami A$$b0
000134807 245__ $$aEvaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma.
000134807 260__ $$aLondon$$bBioMed Central$$c2018
000134807 3367_ $$2DRIVER$$aarticle
000134807 3367_ $$2DataCite$$aOutput Types/Journal article
000134807 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1528116798_28969
000134807 3367_ $$2BibTeX$$aARTICLE
000134807 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134807 3367_ $$00$$2EndNote$$aJournal Article
000134807 520__ $$aWith the advance of modern irradiation techniques, the role of radiotherapy (RT) for intracranial meningioma has increased significantly throughout the past years. Despite that tumor's generally favorable outcome with local control rates of up to 90% after ten years, progression after RT does occur. In those cases, re-irradiation is often difficult due to the limited radiation tolerance of the surrounding tissue. The aim of this analysis is to determine the value of particle therapy with its better dose conformity and higher biological efficacy for re-irradiating recurrent intracranial meningioma. It was performed within the framework of the 'clinical research group heavy ion therapy' and funded by the German Research Council (DFG, KFO 214).Forty-two patients treated with particle RT (protons (n = 8) or carbon ions (n = 34)) for recurrent intracranial meningioma were included in this analysis. Location of the primary lesion varied, including skull base (n = 31), convexity (n = 5) and falx (n = 6). 74% of the patients were categorized high-risk according to histology with a WHO grading of II (n = 25) or III (n = 6), in the remaining cases histology was either WHO grade I (n = 10) or unknown (n = 1). Median follow-up was 49,7 months.In all patients, re-irradiation could be performed safely without interruptions due to side effects. No grade IV or V toxicities according to CTCAE v4.0 were observed. Particle RT offered good overall local control rates with 71% progression-free survival (PFS) after 12 months, 56,5% after 24 months and a median PFS of 34,3 months (95% CI 11,7-56,9). Histology had a significant impact on PFS yielding a median PFS of 25,7 months (95% CI 5,8-45,5) for high-risk histology (WHO grades II and III) while median PFS was not reached for low-risk tumors (WHO grade I) (p = 0,03). Median time to local progression was 15,3 months (Q1-Q3 8,08-34,6). Overall survival (OS) after re-irradiation was 89,6% after 12 months and 71,4% after 24 months with a median OS of 61,0 months (95% CI 34,2-87,7). Again, WHO grading had an effect, as median OS for low-risk patients was not reached whereas for high-risk patients it was 45,5 months (95% CI 35,6-55,3).Re-irradiation using particle therapy is an effective method for the treatment of recurrent meningiomas. Interdisciplinary decision making is necessary to guarantee best treatment for every patient.
000134807 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000134807 588__ $$aDataset connected to CrossRef, PubMed,
000134807 7001_ $$aCzech, Maja$$b1
000134807 7001_ $$aKessel, Kerstin A$$b2
000134807 7001_ $$aHabermehl, Daniel$$b3
000134807 7001_ $$aWeber, Dorothea$$b4
000134807 7001_ $$aRieken, Stefan$$b5
000134807 7001_ $$aBougatf, Nina$$b6
000134807 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b7$$udkfz
000134807 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b8$$udkfz
000134807 7001_ $$aCombs, Stephanie E$$b9
000134807 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-018-1026-x$$gVol. 13, no. 1, p. 86$$n1$$p86$$tRadiation oncology$$v13$$x1748-717X$$y2018
000134807 909CO $$ooai:inrepo02.dkfz.de:134807$$pVDB
000134807 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000134807 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000134807 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000134807 9141_ $$y2018
000134807 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134807 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134807 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000134807 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000134807 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000134807 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000134807 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000134807 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000134807 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134807 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134807 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134807 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000134807 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lMedizinische Physik in der Strahlentherapie$$x0
000134807 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x1
000134807 980__ $$ajournal
000134807 980__ $$aVDB
000134807 980__ $$aI:(DE-He78)E040-20160331
000134807 980__ $$aI:(DE-He78)E050-20160331
000134807 980__ $$aUNRESTRICTED